CLINICAL STUDY: ATRIAL FIBRILLATION
Embolic complications of direct current cardioversion of atrial arrhythmias: association with low intensity of anticoagulation at the time of cardioversion
Mark M. Gallagher, MD*,*,
Brian J. Hennessy, MB ,
Nils Edvardsson, MD ,
Ceara M. Hart, MB ,
Muriel S. Shannon, MD||,
Owen A. Obel, MB*,
Naab M. Al-Saady, PhD* and
A. John Camm, MD*
* Department of Cardiological Sciences, St. George’s Hospital Medical School, London, United Kingdom
Department of Haematology, Northwick Park Hospital, London, United Kingdom
Division of Cardiology, Sahlgrenska University Hospital, Göteborg, Sweden
Department of Cardiology, Cork University Hospital, Cork, Ireland
|| Department of Haematology, St. George’s Hospital Medical School, London, United Kingdom
Manuscript received October 24, 2001;
revised manuscript received February 25, 2002,
accepted June 4, 2002.
* Reprint requests and correspondence: Dr. Mark M. Gallagher, Department of Cardiological Sciences, St. George’s Hospital Medical School, Cranmer Terrace, London SW17 ORE, United Kingdom.
mm.gallagher{at}virgin.net
OBJECTIVES: The goal of this study was to identify the factors responsible for embolic complications of direct current (DC) cardioversion of atrial arrhythmias.
BACKGROUND: Direct current cardioversion of atrial fibrillation (AF) carries a risk of thromboembolism, which is reduced, but not eliminated, by anticoagulation. The risk of embolism after conversion of atrial flutter is believed to be lower. No series to date has included enough patients receiving anticoagulants or enough patients with atrial flutter to estimate the risk in these groups.
METHODS: We reviewed the case records of 1,950 patients who underwent 2,639 attempts at DC cardioversion.
RESULTS: Cardioversion was performed within two days of the apparent onset of the arrhythmia in 443 episodes, 352 without subsequent prolonged anticoagulation with one embolic complication. Cardioversion was preceded by warfarin therapy for  3 weeks in 1,932 instances. No embolic complication occurred in 779 attempts performed with an international normalized ratio (INR) of 2.5 (95% confidence limits 0% to 0.48%). Of 756 cases in which the INR was <2.5 or was not measured before conversion, nine were complicated by thromboembolism. Embolism was significantly more common at an INR of 1.5 to 2.4 than at an INR 2.5 (0.93% vs. 0%, p = 0.012). The incidence of embolism after conversion of atrial flutter or tachycardia was similar to that after cardioversion of AF (0.72% vs. 0.46%, p = NS).
CONCLUSIONS: The INR should be 2.5 at the time of cardioversion if the duration of AF is uncertain or >2 days. Cardioversion of atrial flutter presents similar risks and requires similar anticoagulation.
|
Abbreviations and Acronyms
| | AF | | atrial fibrillation | | DC | | direct current | | INR | | international normalized ratio |
|
This article has been cited by other articles:
|
|
|
|
 
D. G. Wyse
Cardioversion of Atrial Fibrillation for Maintenance of Sinus Rhythm: A Road to Nowhere
Circulation,
October 6, 2009;
120(14):
1444 - 1452.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Camm, P. Kirchhof, G. Y.H. Lip, I. Savelieva, and S. Ernst
CHAPTER 29 Atrial Fibrillation
ESC Textbook of Cardiovascular Medicine,
January 1, 2009;
2(1):
med-9780199566990-chapter - med-9780199566990-chapter.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. R. Hiatt, A. M. Lincoff, and R. A. Harrington
Acute Pharmacological Conversion of Atrial Fibrillation to Sinus Rhythm: Is Short-Term Symptomatic Therapy Worth It? A Report From the December 2007 Meeting of the Cardiovascular and Renal Drugs Advisory Committee of the Food and Drug Administration
Circulation,
June 3, 2008;
117(22):
2956 - 2957.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. E. Singer, G. W. Albers, J. E. Dalen, M. C. Fang, A. S. Go, J. L. Halperin, G. Y. H. Lip, and W. J. Manning
Antithrombotic Therapy in Atrial Fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest,
June 1, 2008;
133(6_suppl):
546S - 592S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Kirchhof, A. Auricchio, J. Bax, H. Crijns, J. Camm, H.-C. Diener, A. Goette, G. Hindricks, S. Hohnloser, L. Kappenberger, et al.
Outcome parameters for trials in atrial fibrillation: executive summary: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA)
Eur. Heart J.,
November 2, 2007;
28(22):
2803 - 2817.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Kirchhof, A. Auricchio, J. Bax, H. Crijns, J. Camm, H.-C. Diener, A. Goette, G. Hindricks, S. Hohnloser, L. Kappenberger, et al.
Outcome parameters for trials in atrial fibrillation: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association
Europace,
November 1, 2007;
9(11):
1006 - 1023.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L Kalra, G Y H Lip, and on behalf of the Guideline Development Group for t
Antithrombotic treatment in atrial fibrillation
Heart,
January 1, 2007;
93(1):
39 - 44.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C J Mann, S Kendall, G Y H Lip, and on behalf of the Guideline Development Group for t
Acute management of atrial fibrillation with acute haemodynamic instability and in the postoperative setting
Heart,
January 1, 2007;
93(1):
45 - 47.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. F. Scholten, A. S. Thornton, J. M. Mekel, P. J. Koudstaal, and L. J. Jordaens
Anticoagulation in atrial fibrillation and flutter
Europace,
January 1, 2005;
7(5):
492 - 499.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. E. Singer, G. W. Albers, J. E. Dalen, A. S. Go, J. L. Halperin, and W. J. Manning
Antithrombotic Therapy in Atrial Fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest,
September 1, 2004;
126(3_suppl):
429S - 456S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G Corrado, S Beretta, L Sormani, G Tadeo, G Foglia-Manzillo, L.M Tagliagambe, and M Santarone
Prevalence of atrial thrombi in patients with atrial fibrillation/flutter and subtherapeutic anticoagulation prior to cardioversion
Eur J Echocardiogr,
August 1, 2004;
5(4):
257 - 261.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Takami, M. Suzuki, K. Sugi, and T. Ikeda
Time course for resolution of left atrial appendage stunning after catheter ablation of chronic atrial flutter
J. Am. Coll. Cardiol.,
June 18, 2003;
41(12):
2207 - 2211.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
How Much Anticoagulation When Cardioverting Atrial Arrhythmias?
Journal Watch Cardiology,
November 8, 2002;
2002(1108):
4 - 4.
[Full Text]
|
|
|
|
|
|
|
B. Olshansky
High intensity anticoagulation for cardioversion of atrial arrhythmias? The shocking truth
J. Am. Coll. Cardiol.,
September 4, 2002;
40(5):
934 - 936.
[Full Text]
[PDF]
|
|
|
|
